


## Aleksander Bilewicz



### *Affiliation and Official Address:*

Professor, head of Laboratory of Radiopharmaceuticals  
Department of Radiochemistry,  
Institute of Nuclear Chemistry and Technology  
03-195 Warsaw, POLAND.  
Tel: +48 22 504 13 57  
Fax: +48 22 811 15 32  
e-mail: a.bilewicz@ichtj.waw.pl

### *Education:*

**1971-76:** University studies at the Warsaw University - Department of Chemistry  
**1976:** MSc in Chemistry - Warsaw University.  
**1986:** PhD in Chemistry - Technical University of Warsaw  
**1998:** DSc in Chemistry - Institute of Nuclear Chemistry and Technology  
**2006:** Professor

### *Career/Employment:*

2006 - Full Professor  
1998 – 2006 Assoc. Prof. Institute of Nuclear Chemistry and Technology  
1986 – 1998 adjunct, Institute of Nuclear Chemistry and Technology  
1976 – 1986 assistant, Institute of Nuclear Chemistry and Technology

### *Scientific visits*

1989, Paul Scherrer Institute, Villigen, Switzerland, IAEA fellowship  
1990, 1992, Paul Scherrer Institute, Villigen, Switzerland, research contracts  
1991, 1993, Lawrence Berkeley Laboratory, University of California, Berkeley, USA,  
1995 research contracts  
1998, 2004, Joint Institute of Nuclear Research, Dubna, Russia, cyclotron experiment  
2005, 2006 Chalmers Technical University, Goeteborg, Szwecja, scientific visit in field of  
radiopharmaceutical chemistry  
2006, 2007 Instituto Tecnológico e Nuclear, Sacaven, Portugal, scientific visit in field of  
radiopharmaceutical chemistry

### *Fields of interest:*

**Radiopharmaceutical chemistry,**

- accelerator and reactor production of radionuclides:  $^{43}\text{Sc}$ ,  $^{44}\text{Sc}$ ,  $^{47}\text{Sc}$ ,  $^{211}\text{At}$ ,  $^{105}\text{Rh}$ ,
- complexes of  $^{47}\text{Sc}$ ,  $^{103\text{m},105}\text{Rh}$ , and  $^{211}\text{At}$  as precursors of therapeutic radiopharmaceuticals,
- nanozeolite, barium ferrite nanoparticle bioconjugates labeled with  $^{223}\text{Ra}$ ,
- magnetic nanoparticles labeled with  $\beta$ - and  $\alpha$ emitters for combination of internal radiotherapy and hyperthermia
- $^{211}\text{At}$ -gold cluster– trastuzumab for radioimmunotherapy

Number of papers in journals (by Web of Science): 100

Number of communications to scientific meetings: 265